Morgan Stanley Maintains Overweight on 2seventy bio, Raises Price Target to $29
Morgan Stanley analyst Matthew Harrison maintains 2seventy bio (NASDAQ:TSVT) with a Overweight and raises the price target from $27 to $29.
Guggenheim Initiates Coverage On 2seventy bio with Buy Rating, Announces Price Target of $30
Guggenheim analyst Kelsey Goodwin initiates coverage on 2seventy bio (NASDAQ:TSVT) with a Buy rating and announces Price Target of $30.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
2seventy bio Q2 EPS $(2.02) Up From $(3.60) YoY, Sales $13.48M Up From $7.33M YoY
2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(2.02) per share. This is a 43.89 percent increase over losses of $(3.60) per share from the same period last year. The company reported $13.48 million in sales
Goldman Sachs Initiates Coverage On 2seventy bio with Buy Rating, Announces Price Target of $26
Goldman Sachs analyst Salveen Richter initiates coverage on 2seventy bio (NASDAQ:TSVT) with a Buy rating and announces Price Target of $26.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
